ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
ChromaDex Corporation (CDXC)
NASDAQ:AMEX Investor Relations:
investors.chromadex.com
Company Research
Source: Business Wire
Judges award Niagen for its “high-quality, unparalleled” healthy aging research LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce that its flagship ingredient, Niagen® (patented nicotinamide riboside, NR), the most efficient and high-quality NAD+ booster and the active ingredient in the company’s consumer supplement, Tru Niagen®, has been awarded the NutraIngredients EU Healthy Ageing Ingredient of the Year Award. This recognition underscores the significant contributions Niagen has made to the field of healthy aging and its role in supporting cellular health and healthspan.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240522381230/en/Niagen awarded the 2024 NutraIngredients EU Healthy Ageing Ingredient of the Year Award (Graphic: Business Wire)Recognized globally as a benchmark for excellence, th
Show less
Read more
Impact Snapshot
Event Time:
CDXC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXC alerts
High impacting ChromaDex Corporation news events
Weekly update
A roundup of the hottest topics
CDXC
News
- Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair [Yahoo! Finance]Yahoo! Finance
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) [Yahoo! Finance]Yahoo! Finance
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)Business Wire
- ChromaDex Co. (NASDAQ: CDXC) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $6.00 price target on the stock.MarketBeat
- ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag [Yahoo! Finance]Yahoo! Finance
CDXC
Earnings
- 5/8/24 - Beat
CDXC
Analyst Actions
- 5/9/24 - HC Wainwright
CDXC
Sec Filings
- 5/8/24 - Form 8-K
- 5/8/24 - Form 10-Q
- 4/25/24 - Form ARS
- CDXC's page on the SEC website